CTNNB1 and prostate cancer: For instance, in the context of myeloid leukemia, YBX1 has been shown to contribute to the survival of leukemia cells by selectively stabilizing Bcl-2 protein levels through an m6A-dependent regulatory mechanism, and enhances the HIF-1α protein expression by directly binding to and activating translation of HIF-1α messages [29]; YBX1 plays a critical role in the invasive and metastatic processes of breast cancer through its regulatory influence on MMP1 and beta-catenin [31]; and it promotes prostate cancer progression through Raf/MEK/ERK signaling [32].